ScholarIQanswers from OpenAlex

Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer

PaperCitations, authors & open-access status

Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer have?

ScholarIQcitation count

Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer has 107 citations in the OpenAlex counts ScholarIQ stores.

When was Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer published?

ScholarIQyear

Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer has 2021 year in the ScholarIQ index.

What is the open-access status of Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer?

ScholarIQoa status

Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer has green oa status in the ScholarIQ index.

What is the DOI of Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer?

ScholarIQdoi

The DOI for Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer is on the source record.

What is the PMID of Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer?

ScholarIQpmid

The PMID for Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer is on the source record.

What is the OpenAlex record for Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer?

ScholarIQopenalex

The OpenAlex for Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial